Imagine a birth control method that’s been around for over two decades, is safe, effective, and empowers individuals to take control of their reproductive health—yet remains largely unknown to both doctors and patients. Sounds shocking, right? Self-administered injectable contraception, a game-changer in family planning, is exactly that overlooked gem. Despite its potential, a recent study reveals that only about a quarter of reproductive health experts in the U.S. prescribe it, and many aren’t even aware it exists. But here’s where it gets controversial: could biases, lack of awareness, or systemic barriers be keeping this option in the shadows?
Published on January 8 in the journal Obstetrics & Gynecology, this groundbreaking study is the first to explore why self-administered injectable contraception hasn’t gained traction in the U.S. (https://journals.lww.com/ogopen/_layouts/15/oaks.journals/PageNotFound.aspx). According to Jennifer Karlin (https://profiles.ucsf.edu/jennifer.karlin), MD, PhD, a UCSF associate professor and the study’s senior author, the issue boils down to a simple yet glaring problem: ‘Since most physicians don’t know this is an option, patients don’t know about it.’ She emphasizes, ‘It’s safe, effective, and puts the control in patients’ own hands. We should be talking about and offering it without biases.’
The study surveyed 422 clinicians who regularly prescribe birth control, uncovering a surprising gap: only about a third of those aware of self-administered injectables actually recommend it. Why the hesitation? Providers cited concerns like patients’ ability to self-inject, uncertainty about pharmacy availability, and a lack of standardized counseling protocols. But is this skepticism justified, or are these just hurdles that could be easily overcome with better education and support?
Let’s break it down further. Depot medroxyprogesterone acetate (DMPA), the synthetic hormone in this contraceptive, prevents pregnancy for up to three months by stopping ovulation, thickening cervical mucus, and thinning the uterine lining. It comes in two forms: an intramuscular injection (Depo Provera), administered by a provider, and a subcutaneous version that can be self-injected—similar to the popular GLP-1 weight-loss drugs. The subcutaneous option, approved in 2004, is technically labeled for clinician use but has been safely self-administered by patients for years, especially in regions like sub-Saharan Africa.
And this is the part most people miss: while DMPA has potential side effects like reduced bone mineral density, weight gain, and a rare benign brain tumor called meningioma (https://www.ucsf.edu/news/2025/10/430821/could-birth-control-shot-increase-your-risk-brain-tumor), these risks are low. Isn’t it worth having an open conversation about the benefits and risks, rather than letting fear or misinformation dictate choices?
Interestingly, the study found that self-injectable contraception gained popularity in the U.S. during the COVID-19 pandemic, with over half of surveyed prescribers learning about it between 2020 and 2022. Yet, providers in states with restricted abortion access were less likely to prescribe it. Why? Could political or ideological factors be influencing medical decisions?
International and national guidelines recommend making this option accessible to all, but barriers like insufficient educational materials, lack of staff support, and limited consultation time persist. The authors propose solutions: an education campaign for clinicians, FDA approval for self-administered versions, insurance coverage, and streamlined clinic workflows.
But here’s the real question: Why isn’t this already happening? Is it a lack of will, resources, or awareness? Or is there a deeper resistance to empowering individuals with more reproductive choices?
The study’s authors, including Chase Clark of UC Davis, An-Lin Cheung, PhD, and Laura Creason, MS, of the University of Missouri-Kansas City, received funding from the Society of Family Planning (SFPRF16). They have no conflicts of interest to disclose.
So, what do you think? Should self-administered injectable contraception be more widely promoted, or are the concerns around it valid? Let’s spark a conversation—share your thoughts in the comments below!
